Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.
PNS Pharma recently released a report titled “Humira Biosimilars Clinical Trial Insight” that includes clinical data on 33 potential new drugs that have a similar action to Humira (adalimumab), an ... Read more
Treatment of rheumatoid arthritis (RA) with Remicade (infliximab) is associated with lower rates of discontinuation among patients, compared to treatment with CT-P13 (a biosimilar of infliximab), according to results presented by ... Read more
Treatment with the investigative drug baricitinib is more effective than Humira (adalimumab), an FDA-approved therapy, in improving joint pain, stiffness and tiredness in patients with rheumatoid arthritis (RA) who have an ... Read more
Pfizer recently presented encouraging results on the effectiveness and safety of the company’s product Xeljanz (tofacitinib citrate) for the treatment of rheumatoid arthritis (RA). The data was presented at the ACR/ARHP Annual ... Read more
Treatment with baricitinib improves joint damage in patients with rheumatoid arthritis (RA) who have an inadequate response or intolerance to conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs), according to the results of ... Read more
The European Commission has approved the use of Orencia (abatacept) by intravenous infusion and injection in combination with methotrexate (MTX) to treat highly active and progressive rheumatoid arthritis (RA) in ... Read more